To explore the effects of cetirizine combined with montelukast sodium on sleep, quality of life,immunity, inflammatory factors and safety in children with cough variant asthma(CVA).
A total of 71 children with CVA admitted to our hospital from December 2022 to October 2024 were selected as the research subjects and randomly divided into the experimental group of 35 cases and the control group of 36 cases. Both groups received basic treatment. The control group was treated with montelukast sodium, and the experimental group was treated with cetirizine on this basis. The treatment course for both groups was one week. The apnea-hypopnea index, the lowest nocturnal blood oxygen saturation, quality of life and inflammatory factors of the two groups before and after treatment were detected,and the occurrence of adverse reactions was statistically analyzed.
After treatment, the minimum nocturnal blood oxygen saturation, immunoglobulin(Ig)A, interferon-γ, cluster of differentiation(CD)4+, CD4+/CD8+ in both groups increased compared with those before treatment, and the experimental group was higher than the control group. The differences were significant(P<0.05). The scores of sleep disorders, physical symptoms, poor mood, daytime functional status and total score in both groups after treatment were lower than those before treatment. The scores in the experimental group were lower than those in the control group, and the differences were significant(P<0.05). The apnea-hypopnea index, C reactive protein, monocyte chemoattractant protein-1, interleukin(IL)-4, transforming growth factor -β, vascular endothelial growth factor, IgE, IL-13, and CD8+ in both groups decreased compared with those before treatment, and the experimental group was lower than the control group, with significant differences(P<0.05). There was no significant difference in the total incidence of abdominal pain and diarrhea, nausea and vomiting, rash and dizziness between the two groups(P>0.05).
Cetirizine combined with montelukast sodium in the treatment of children with CVA can improve sleep structure, enhance quality of life and immune function, reduce the levels of inflammatory factors, and has good safety.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |